JP2001510028A - ｐ２７およびその融合物で血管増殖性疾患を処置する方法 - Google Patents

ｐ２７およびその融合物で血管増殖性疾患を処置する方法

Info

Publication number
JP2001510028A
JP2001510028A JP2000502802A JP2000502802A JP2001510028A JP 2001510028 A JP2001510028 A JP 2001510028A JP 2000502802 A JP2000502802 A JP 2000502802A JP 2000502802 A JP2000502802 A JP 2000502802A JP 2001510028 A JP2001510028 A JP 2001510028A
Authority
JP
Japan
Prior art keywords
cells
cell
expression
vector
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000502802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510028A5 (enExample
Inventor
ギャリー ジェイ． ナベル，
エリザベス ジー． ナベル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2001510028A publication Critical patent/JP2001510028A/ja
Publication of JP2001510028A5 publication Critical patent/JP2001510028A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2000502802A 1997-07-21 1998-07-21 ｐ２７およびその融合物で血管増殖性疾患を処置する方法 Pending JP2001510028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/897,333 1997-07-21
US08/897,333 US6177272B1 (en) 1997-07-21 1997-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
PCT/US1998/015025 WO1999003508A2 (en) 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF

Publications (2)

Publication Number Publication Date
JP2001510028A true JP2001510028A (ja) 2001-07-31
JP2001510028A5 JP2001510028A5 (enExample) 2006-01-05

Family

ID=25407780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000502802A Pending JP2001510028A (ja) 1997-07-21 1998-07-21 ｐ２７およびその融合物で血管増殖性疾患を処置する方法

Country Status (8)

Country Link
US (2) US6177272B1 (enExample)
EP (1) EP0998307B1 (enExample)
JP (1) JP2001510028A (enExample)
AT (1) ATE342067T1 (enExample)
AU (1) AU8502198A (enExample)
CA (1) CA2295199C (enExample)
DE (1) DE69836139T2 (enExample)
WO (1) WO1999003508A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
CA2362995A1 (en) 1999-03-01 2000-09-08 Cell Genesys, Inc. Anti-neoplastic compositions and uses thereof
US6413943B1 (en) * 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
JP4684512B2 (ja) * 1999-09-22 2011-05-18 信之 宮坂 ｐ２１Ｃｉｐ１リウマチ治療剤
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
DE60124285T3 (de) * 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes Beschichtete medizinische geräte
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020098998A1 (en) * 2001-01-22 2002-07-25 Marks Andrew R. P27 prevents cellular migration
US20030013638A1 (en) * 2001-01-22 2003-01-16 Marks Andrew R. P27 prevents cellular migration
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
CA2715765A1 (en) * 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6355774B1 (en) 1994-01-07 2002-03-12 Fred Hutchinson Cancer Research Center Isolated p27 protein
WO1996002140A1 (en) 1994-07-15 1996-02-01 Sloan-Kettering Institute For Cancer Research ISOLATED p27 PROTEIN AND METHODS FOR ITS PRODUCTION AND USE
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6242575B1 (en) 1994-01-07 2001-06-05 Fred Hutchinson Institute For Cancer Research Antibodies for detecting p27 protein
US5688665A (en) 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
AU5253998A (en) * 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
EP0998307A2 (en) 2000-05-10
US6884431B1 (en) 2005-04-26
DE69836139D1 (de) 2006-11-23
DE69836139T2 (de) 2007-08-16
AU8502198A (en) 1999-02-10
WO1999003508A3 (en) 1999-04-08
CA2295199A1 (en) 1999-01-28
WO1999003508A9 (en) 1999-05-14
ATE342067T1 (de) 2006-11-15
CA2295199C (en) 2007-07-03
WO1999003508A2 (en) 1999-01-28
US6177272B1 (en) 2001-01-23
EP0998307B1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
EP0998307B1 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
US6057300A (en) Methods for treating cancers and restenosis with p21
USRE37933E1 (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
KR100304033B1 (ko) 세포증식질환치료용약제학적조성물
JP3778930B2 (ja) 動脈平滑筋細胞増殖の抑制
US6737523B1 (en) Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
US20030157494A1 (en) Smooth muscle cell promoter and uses thereof
KR20010020259A (ko) 말단이 잘린 ｖｅｇｆ-관련 단백질
JP2001525173A (ja) 遺伝子発現を誘導するための組成物および方法
JP2002541829A (ja) 遺伝子治療および治療的スクリーニングに有用なｅＮＯＳ変異体
US20020048577A1 (en) Methods and devices to modulate the wound response
JP2003502065A (ja) 高められた増殖能を持つ心筋細胞、およびその製造および使用法
Zhang et al. Magnetic nanosphere-guided site-specific delivery of vascular endothelial growth factor gene attenuates restenosis in rabbit balloon-injured artery
US7202212B2 (en) Method for PR-39 peptide mediated selective inhibition of lκBα degradation
US7087582B1 (en) Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
JP2003500336A (ja) （自己）免疫疾患の治療におけるアポトーシス誘発剤の使用
WO2010053199A1 (ja) 前立腺癌の治療用医薬組成物及び前立腺癌の治療方法
JPH11506325A (ja) Δｐ６２、その変異体、核酸配列及びこれらの使用
US7169604B1 (en) Method for PR-39 peptide mediated selective inhibition of IκBα degradation
JP2000507099A (ja) 平滑筋細胞ｌｉｍ蛋白質
MXPA97007549A (en) Viral vectors and their use to treat disordershiperproliferativos, in particular resteno

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118